More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.38B
EPS
-1.31
P/E ratio
--
Price to sales
9.54
Dividend yield
--
Beta
1.687289
Previous close
$26.18
Today's open
$24
Day's range
$23.19 - $29.50
52 week range
$16.50 - $50.81
show more
CEO
Elizabeth Barrett
Employees
300
Headquarters
Princeton, NJ
Exchange
NASDAQ Global Market
Shares outstanding
49047823
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
UroGen: Opportunity Builds As Rough Patch Gets Brutal
UroGen Pharma is rated a 'Buy' at a depressed ~$1.21B market cap, with potential for ~65% upside in 2027. Management has established a promising setup, featuring two approved products—Jelmyto and Zusdori—leveraging the proprietary RT Gel delivery system. Jelmyto's sales have stalled below initial expectations, while Zusdori is positioned for significant growth and could drive future upside.
Seeking Alpha • Nov 9, 2026

The Gel That Became a Business
Zosturi quarterly net product revenue reached $68 million. Repeat prescribers expanded to 50% of total Zosturi writers.
The Motley Fool • Nov 4, 2026

Urogen Pharma Q3 Earnings Call Highlights
Urogen Pharma NASDAQ: URGN reported third-quarter revenue of $89 million, more than triple the $27.5 million recorded a year earlier, as sales of bladder cancer treatment ZUSDURI continued to grow. The company said it expects to achieve profitability and generate positive cash flow in the fourth quarter of 2026.
MarketBeat • Nov 4, 2026

UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript
UroGen Pharma Ltd. ( URGN ) Q3 2026 Earnings Call November 4, 2026 10:00 AM EST Company Participants Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer Christopher Degnan - Chief Financial Officer Conference Call Participants Leland Gershell - Oppenheimer & Co. Inc., Research Division Tara Bancroft - TD Cowen, Research Division Raghuram Selvaraju - H.C.
Seeking Alpha • Nov 4, 2026

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
ZUSDURI ® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen's NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date set for June 14, 2027 Announced first patient dosed in the UGN-501 Phase 1 trial Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
GlobeNewsWire • Nov 4, 2026

Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $0.69 per share a year ago.
Zacks Investment Research • Nov 4, 2026

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
GlobeNewsWire • Nov 3, 2026

UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
Phase 1 clinical trial to evaluate local intravesical administration of UGN-501 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation PRINCETON, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
GlobeNewsWire • Nov 2, 2026

UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTO Results demonstrate sustained disease control through extended follow-up among patients who achieved a complete response after treatment with JELMYTO No progression to high-grade disease was observed during extended follow-up PRINCETON, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
GlobeNewsWire • Oct 28, 2026

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET
GlobeNewsWire • Oct 27, 2026

¹ Disclosures

Open an M1 investment account to buy and sell UroGen Pharma Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.